Multiresistant Acinetobacter baumannii infections: Epidemiology and management

Current Opinion in Infectious Diseases

Volumn 23, Issue 4, 2010, Pages 332-339

  Garnacho Montero, José ^a   Amaya Villar, Rosario ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Acinetobacter baumannii; epidemiology; infection; multiresistance; treatment

Indexed keywords

AMPICILLIN; BETA LACTAM DERIVATIVE; CARBAPENEM DERIVATIVE; COLISTIN; DORIPENEM; IMIPENEM; MEROPENEM; RIFAMPICIN; SULBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL STRAIN; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; HUMAN; MENINGITIS; MULTIDRUG RESISTANCE; NONHUMAN; PNEUMONIA; REVIEW; VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER INFECTIONS; DRUG EFFECTS; PATHOGENICITY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 77954888053     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833ae38b     Document Type: Review

References (73)

1. Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother 2008; 9:587-599.
2. Rodríguez-Baño J, Cisneros JM, Fernández-Cuenca F, et al., Grupo de Estudio de Infección Hospitalaria (GEIH). Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 2004; 25:819-824.
3. Shelburne SA 3rd, Singh KV, White AC Jr, et al. Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol 2008; 46:198-205.
4. Wang H, Chen M, Ni Y, et al. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int J Antimicrob Agents 2010; 35:227-234.
5. Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect 2009; 73:355-363.
6. Karageorgopoulos DE, Falagas ME. Current control and treatment of multi-drug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008; 8:751-762.
7. García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, et al. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med 1999; 27:1794-1799.
8. Lortholary O, Fagon JY, Buu Hoi A, et al. Colonization by Acinetobacter baumanii in intensive-care-unit patients. Infect Control Hosp Epidemiol 1998; 19:188-190.
9. Wilks M, Wilson A, Warwick S, et al. Control of an outbreak of multidrug-resistant Acinetobacter baumannii: calcoaceticus colonization and infection in an intensive care unit (ICU) without closing the ICU or placing patients in isolation. Infect Control Hosp Epidemiol 2006; 27:654-658.
10. Wagenvoort JH. Epidemic Acinetobacter baumannii strain with MRSA-like behaviour carried by healthcare staff. Eur J Clin Microbiol Infect Dis 2002; 21:326-327.
11. El Shafie SS, Alishaq M, Leni Garcia M. Investigation of an outbreak of multidrug-resistant Acinetobacter baumannii in trauma intensive care unit. J Hosp Infect 2004; 56:101-105.
12. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358:1271-1281.
13. Brooks SE, Walczak MA, Rizwanullah H. Are we doing enough to contain Acinetobacter infections. Infect Control Hosp Epidemiol 2000; 21:304.
14. Hsueh PR, Teng LJ, Chen CY, et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a University hospital, Taiwan. Emerg Infect Dis 2002; 8:827-831.
15. Fernandez-Cuenca F, Pascual A, et al. Diversidad clonal y sensibilidad a los antimicrobianos de Acinetobacter baumannii aislados en hospitales espa-ñoles. Enferm Infecc Microbiol Clin 2004; 22:267-271.
16. Abbo A, Navon-Venezia S, Hammer-Muntz O, et al. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005; 11:22-29.
17. Monterrubio-Villar J, Gonzalez-Velasco C, Valdezate-Ramos S, et al. Outbreak of multiresistant Acinetobacter baumannii in a polyvalent intensive care unit: clinical, epidemiological analysis and PFGE-printing evolution. Eur J Clin Microbiol Infect Dis 2009; 28:1281-1284.
18. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5:939-951.
19. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317.
20. Spencer RC. Predominant pathogens found in the european prevalence of infection in intensive care study. Eur J Clin Microbiol Infect Dis 1996; 15:281-285.
21. Vincent JL, Rello J, Marshall J, et al., EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-2329.
22. Scott P, Deye G, Srinivasan A, Murray C, et al. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military healthcare system associated with military operations in Iraq. Clin Infect Dis 2007; 44:1577-1584.
23. Bou G, Cervero G, Dominguez MA, et al. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A baumannii is not due solely to the presence of b-lactamases. J Clin Microbiol 2000; 38:3299-3305.
24. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:2065-2069.
25. Joly-Guillou ML, Wolf M, Pocidalo JJ, et al. Use of a new mouse model of A baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother 1997; 41:345-351.
26. Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermen-tative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 2009; 63:426-433.
27. Marti S, Sanchez-Cespedes J, Alba V, Vila J. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int J Antimicrob Agents 2009; 33:181-182.
28. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multiresistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-1118.
29. Wood GC, Hanes SD, Croce MA, et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34:1425-1430.
30. Montero A, Ariza J, Corbella X, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54:1085-1091.
31. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31:649-655.
32. Lautenbach E, Synnestvedt M, Weiner MG, et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 2009; 30:1186-1192.
33. Reinert RR, Low DE, Rossi F, et al. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007; 60:1018-1029.
34. Rodriguez-Hernandez MJ, Cuberos L, PichardoC, et al. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother 2001; 47:479-482.
35. Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993; 167:448-451.
36. Levin ASS, Levy CE, Manrique AE, et al. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbac-tam. Int J Antimicrob Agents 2003; 21:58-62.
37. Oliveira MS, Prado GV, Costa SF, et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008; 61:1369-1375.
38. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 2007; 39:38-43.
39. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56:432-436.
40. Jiménez-Mej́?as ME, Pachón J, Becerril B, et al. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis. 1997. 24. 932-935.
41. Rodríguez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Aci-netobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother 2008; 61:908-913.
42. Brauers J, Frank U, Kresken M, et al. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA Group 3 strains. Clin Microbiol Infect 2005; 11:24-30.
43. Pachón-Ibañez ME, Fernández-Cuenca F, Docobo-Pérez F, et al. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother 2006; 58:689-692.
44. Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54:1165-1172.
45. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY Antimicrobial Surveillance Programme (2001-2004). Clin Microbiol Infect 2006; 12:315-321.
46. Livermore DM, Hill RL, Thomson H, et al., C-MRAB Study Group. Antimicrobial treatment and clinical outcome for infections with carbapenem-and multiply-resistant Acinetobacter baumannii around London. Int J Antimicrob Agents 2010; 35:19-24.
47. Rodriguez-Hernandez MJ, Jiménez-Mejias ME, Pichardo C, et al. Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis. Clin Microbiol Infect 2004; 10:581-584.
48. Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus b-lactams, aminoglucosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant A. baumannii. Antimicrob Agents Chemother 2002; 46:1946-1952.
49. Levin ASS, Barone AA, Penço, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-1011.
50. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006; 4:138-146.
51. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in acinetobacter and pseudomonas infections: a prospective cohort study. Intensive Care Med 2005; 31:1058-1065.
52. Rios FG, Luna CM, Maskin B, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 2007; 30:307-313.
53. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33:1162-1167.
54. Michalopoulos A, Kasiakou SK, Pastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Critical Care 2005; 9:R53-R59.
55. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008; 102:407-412.
56. KorbilaIP, Michalopoulos A, Rafailidis PI, etal. Inhaled colistin as adjunctive to intravenous colistin for the treatment of microbiologically documented VAP: a comparative cohort study. Clin Microbiol Infect 2009 [Epub ahead of print].
57. Rodríguez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Aci-netobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. Antimicrob Chemother 2008; 61:908-913.
58. Falagas ME, Kasiakou SK, Kofteridis DP, etal. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006; 25:596-599.
59. Oliveira MS, Prado GV, Costa SF, et al. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 2009; 65:431-434.
60. Arroyo LA, Mateos I, Gonzalez V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 2009; 53:1295-1296.
61. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59:128-131.
62. Fernandez-Mazarrasa C, Mazarrasa O, Calvo J, et al. High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by Etest. J Clin Microbiol 2009; 47:827-829.
63. Pichardo C, Pachon-Ibanez ME, Docobo-Perez F, etal. Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia. Eur J Clin Microbiol Infect Dis 2010; 29:527-531.
64. Burkhardt O, Rauch K, Kaever V, et al. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agent 2009; 34:101-102.
65. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007; 27:980-987.
66. Curcio D, Fernández F, Vergara J, et al. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009; 21:58-62.
67. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acineto-bacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62:45-55.
68. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63:775-780.
69. Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of Pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis 2005; 37:195-199.
70. Kuo LC, Lai CC, Liao CH, et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Micro-biol Infect 2007; 13:196-198.
71. Saballs M, Pujol M, Tuban F, et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006; 58:697-700.
72. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53:274-278.
73. Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61:417-420.